In November, the healthcare sector of the S&P 500 saw a notable increase in short selling. The average short interest jumped from 1. 97% to 2. 12%. This means more investors are betting against the sector's future performance. Leading the pack, Moderna (MRNA) remains the most shorted stock in this g
Moderna's latest flu vaccine trial results are in, and they're looking good. The company's experimental mRNA-based flu shot showed a stronger immune response than the standard flu vaccine currently in use. This is big news, especially since Moderna is also working on a combo shot that targets both f
The US Department of Health and Human Services recently made a bold move. They ended a contract with Moderna. The contract was for developing an mRNA vaccine for bird flu. The reason given was that mRNA technology is not well-tested. This decision sparked a response from Pfizer's CEO, Dr. Albert Bou
The Food and Drug Administration has given the green light to a new, lower-dose Covid-19 vaccine from Moderna. This vaccine is specifically for adults aged 65 and older, as well as those between 12 and 64 who have health conditions that put them at higher risk for severe Covid-19. It is important to
The U. S. government has taken a surprising step back in its fight against potential health threats. The Department of Health and Human Services (HHS) recently canceled a significant contract with Moderna, a biotech company known for its COVID-19 vaccine. This contract, worth $766 million, was aimed
The United States government is putting a big chunk of money, about $590 million, into developing a bird flu vaccine. The company Moderna will use this money to keep working on a vaccine that protects against the H5 and H7 types of bird flu. This isn't the first time they're getting help; earlier th
